This post analyses the Indian Patent Office’s rejection of Pfizer’s Tofacitinib patent under Section 3(d). The decision addresses issues of novelty, inventive step, and the requirement for evidence of enhanced efficacy in pharmaceutical patent applications.
Read more about Pfizer falls prey to Section 3(d)Tag: Patent Rejection
Intellectual Property (IP) in India: A Decade of Progress Part 10
The Traditional Knowledge Digital Library has played a pivotal role in India’s efforts to safeguard traditional knowledge from bio-piracy. This post outlines TKDL’s major milestones and its impartial approach to patent examination based on traditional knowledge evidence.
Read more about Intellectual Property (IP) in India: A Decade of Progress Part 10‘Killead’s Patent Application Killed by the Indian Patent Office!
Gilead’s patent for Sofosbuvir was rejected by the Indian Patent Office on grounds of insufficient therapeutic efficacy. This landmark decision enables wider access to affordable generic Hepatitis C treatments in India.
Read more about ‘Killead’s Patent Application Killed by the Indian Patent Office!